Although the complement C3, C4, and anti-dsDNA are conventionally considered as biomarkers for the disease flares of SLE, recent studies have provided some caveats with these laboratory markers of disease activity [5–7]. This evidence concerns the gene C4A and systemic lupus erythematosus.